Document is current
Any future updates will be listed below
-
Authors
Lange, Joshua T. http://orcid.org/0000-0002-4246-6058
Rose, John C. http://orcid.org/0000-0003-1810-4337
Chen, Celine Y. http://orcid.org/0000-0002-1579-024X
Pichugin, Yuriy
Xie, Liangqi
Tang, Jun
Hung, King L. http://orcid.org/0000-0002-3662-4662
Yost, Kathryn E.
Shi, Quanming
Erb, Marcella L.
Rajkumar, Utkrisht
Wu, Sihan http://orcid.org/0000-0001-8329-7492
Taschner-Mandl, Sabine http://orcid.org/0000-0002-1439-5301
Bernkopf, Marie http://orcid.org/0000-0001-6650-4592
Swanton, Charles http://orcid.org/0000-0002-4299-3018
Liu, Zhe http://orcid.org/0000-0002-3592-3150
Huang, Weini http://orcid.org/0000-0002-9016-2665
Chang, Howard Y. http://orcid.org/0000-0002-9459-4393
Bafna, Vineet http://orcid.org/0000-0002-5810-6241
Henssen, Anton G. http://orcid.org/0000-0003-1534-778X
Werner, Benjamin http://orcid.org/0000-0002-6857-8699
Mischel, Paul S. http://orcid.org/0000-0002-4560-2211
-
Funding
Funding for this research was provided by:
National Brain Tumor Society
U.S. Department of Health & Human Services | National Institutes of Health (R01-CA238349, U24CA264379, 1R01GM114362)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NS047101)
Howard Hughes Medical Institute
Barts Charity Lectureship MGU045
A.P. Giannini Foundation
- License Information
-
More Information
Article History
Received: 16 February 2022
Accepted: 1 August 2022
First Online: 19 September 2022
Competing interests
: P.S.M. is cofounder of Boundless Bio. He has equity and chairs the scientific advisory board, for which he is compensated. V.B. is a cofounder, consultant, scientific advisory board member and has an equity interest in Boundless Bio. and Abterra Biosciences. The terms of this arrangement have been reviewed and approved in accordance with its conflict-of-interest policies. H.Y.C. is a cofounder of Accent Therapeutics, Boundless Bio, Cartography Biosciences, Orbital Therapeutics, and advisor of 10X Genomics, Arsenal Biosciences and Spring Discovery. J.T.L. was employed by Boundless Bio after completing this work. C.S. acknowledges grant support from AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Pfizer, Roche-Ventana, Invitae (previously ArcherDX, collaboration in minimal residual disease sequencing technologies) and Ono Pharmaceutical. He is an AstraZeneca advisory board member and chief investigator for the AZ MeRmaiD 1 and 2 clinical trials and is also chief investigator of the NHS-Galleri trial. He has consulted for Amgen, AstraZeneca, Pfizer, Novartis, GSK, MSD, Bristol Myers Squibb, Illumina, Genentech, Roche-Ventana, GRAIL, Medicxi, Metabomed, Bicycle Therapeutics, Roche Innovation Centre Shanghai and the Sarah Cannon Research Institute. C.S. had stock options in ApoGen Biotechnologies and GRAIL until June 2021, has currently stock options in Epic Bioscience and Bicycle Therapeutics, and has stock options and is a cofounder of Achilles Therapeutics. C.S. holds patents relating to assay technology to detect tumor recurrence (PCT/GB2017/053289), targeting neoantigens (PCT/EP2016/059401), identifying patent response to immune checkpoint blockade (PCT/EP2016/071471), determining human leukocyte antigen loss of heterozygosity (PCT/GB2018/052004), predicting survival rates of patients with cancer (PCT/GB2020/050221), identifying patients who respond to cancer treatment (PCT/GB2018/051912), a US patent relating to detecting tumor mutations (PCT/US2017/28013), methods for lung cancer detection (US20190106751A1) and both European and US patents related to identifying insertion/deletion mutation targets (PCT/GB2018/051892). The other authors declare no competing interests.
